Background: Endothelial dysfunction and arterial stiffening are commonly observed in type 2 diabetes. These abnormalities might be secondary to increased plasma concentrations of homocysteine. We sought to determine whether oral folic acid supplementation, by lowering homocysteine levels, enhanced endothelial function and reduced arterial stiffness in type 2 diabetes.
T ype 2 diabetes mellitus is characterized by early development of atherosclerosis. Although tight control of blood pressure (BP), blood glucose, and serum lipids reduce cardiovascular risk, cardiovascular morbidity and mortality rates remain unacceptably high and the risk factor management is notoriously difficult in these patients. [1] [2] [3] Therefore, the identification of alternative strategies to reduce cardiovascular risk in patients with type 2 diabetes is urgently needed.
Endothelial dysfunction and arterial stiffening are common findings in type 2 diabetes. 4, 5 This might explain, at least partly, the increased cardiovascular morbidity and mortality observed in this condition. 6, 7 Increased plasma concentrations of homocysteine, a highly reactive sulfurcontaining amino acid, are associated with impaired endothelial function and arterial stiffening, the same abnormalities observed in type 2 diabetes. 8, 9 Moreover, plasma homocysteine concentrations represent a strong and independent predictor of cardiovascular morbidity and mortality in this population. 10 Plasma concentrations of the B-vitamin folic acid are inversely correlated with homocysteine plasma concentra-tions. 11 Oral folic acid supplementation safely and effectively lowers homocysteine concentrations within 4 to 6 weeks. 12, 13 We have previously observed reductions between 17% and 24% in homocysteine concentrations with such a regimen.
14 Therefore, folic acid supplementation could potentially mitigate the vascular abnormalities observed in type 2 diabetes. The aim of our study was to investigate the effects of oral folic acid supplementation for 4 weeks on endothelial function and arterial stiffness in patients with type 2 diabetes and no previous cardiovascular events.
Methods Subjects
Twenty-six patients with type 2 diabetes (aged 56.5 Ϯ 0.9 years, range 46 to 65 years; diabetes duration 5.5 Ϯ 0.6 years, means Ϯ SEM) were recruited from diabetic and general medical outpatient clinics and local advertising. The subjects had no history of angina, myocardial infarction, stroke, or peripheral occlusive disease. Hypertension was present in 16 patients. One patient was on 4 antihypertensive drugs, 3 patients were on 3, 4 patients were on 2, and 8 patients were on 1 drug. Antihypertensive treatment included diuretics in 6 patients, angiotensin converting enzyme inhibitors in 7, angiotensin II receptor antagonists in 3, ␤-blockers in 7, calcium channel blockers in 4, and ␣-blockers in 2 patients. Antidiabetic treatment included oral hypoglycemic agents and insulin in 4 patients, oral hypoglycemic agents alone in 19, insulin alone in 2, and diet alone in 1 patient. Microalbuminuria, defined as urinary albumin:creatinine ratio Ն2.5 mg/mmol (men) or Ն3.5 mg/mmol (women), was present in 8 subjects. The study was approved by the local Research Ethics Committee. Each subject gave written informed consent before starting the study.
Protocol
Investigations were performed in a temperature-controlled laboratory (25°to 27°C). The subjects were asked to abstain from cigarette smoking and alcohol consumption from the evening before the study. Each subject underwent three visits. During visit 1, a physical examination and an electrocardiogram were performed, BP (mean of three consecutive readings after the subject was resting for 5 min) and heart rate (HR) were measured, and blood and urine samples were taken (cholesterol, folic acid, vitamin B 12 concentrations, and urinary albumin:creatinine ratio). During visit 2, another blood sample was taken (full blood count, biochemistry, fasting homocysteine, folic acid, and vitamin B 12 ) and the following parameters were measured: forearm arterial blood flow (FABF), pulse wave velocity (PWV), and BP. Then, the subjects were randomly assigned to 4-week treatment with either folic acid (5 mg/d) or identically appearing placebo. The allocation sequence was generated by software located in the Pharmacy Department. Both the investigators and the subjects were blinded to the treatment. The subjects returned after 4 weeks for visit 3, for the reassessment of the parameters measured during visit 2. Both FABF and PWV studies were performed by the same investigator (AAM). Vasodilators were stopped 5 days before each study day. This washout period was considered adequate as the elimination half-life of vasodilators ranged between 11 and 22 hours.
FABF
Endothelial function was assessed by the perfused forearm technique. The brachial artery was cannulated using a 27-gauge cannula connected by an epidural catheter to a constant infusion pump. Forearm arterial blood flow was measured simultaneously in both arms (infused and control forearm) by strain-gauge venous occlusion plethysmography (D.E. Hokanson Inc., Bellevue, WA). Baseline measurements were obtained after each subject rested supine for 20 min. Then, endothelial function was assessed by 8-min intra-arterial infusions of incremental doses of an endothelium-dependent vasodilator (acetylcholine 1.5, 4.5, and 15 g/min; Clinalfa, Laeufelfingen, Switzerland). After a second baseline was obtained, an endotheliumindependent vasodilator was administered (sodium nitroprusside 1, 2, and 4 g/min; David Bull Laboratories, Warwick, UK). The order of acetylcholine and sodium nitroprusside infusion was randomized. The doses of vasodilators used did not have any systemic effect on BP and HR. The FABF measurements were taken during the final 2 min of each infusion rate. Circulation to the hands was excluded 1 min before FABF measurement by inflating a pediatric cuff around the wrist at suprasystolic BP.
PWV
Carotid-radial and carotid-femoral PWV were measured noninvasively by a Complior (Colson, Createch Industrie, Garges les Gonesse, France). This device consists of two acoustic sensors, which detect the pulse wave signals and deliver them to a computerized data acquisition board. The latter samples the data at a frequency of 800 Hz and calculates the transit time between the common carotid and radial or femoral arteries. The measurement of the distance between these points allows the calculation of PWV. 15 Twenty consecutive measurements from the left limbs were performed during each visit and averaged. The coefficient of variation of two previous sets of measurements performed in 7 healthy subjects by the same operator 24 h apart averaged 2.3%.
Homocysteine, Folic Acid, and Vitamin B 12
Fasting venous blood samples were collected into tubes containing disodium EDTA and tubes without anticoagulation. The samples were centrifuged at 1800 g within 30 min, the plasma/serum separated and stored at Ϫ20°C.
Total plasma homocysteine was determined using a fluorescence polarization immunoassay on an IMX analyser (Abbott Diagnostics, Maidenhead, UK). 16 Between-batch imprecision was assessed at homocysteine concentrations of 7.0, 12.5, and 25.5 mol/L and coefficients of variation of 2.4%, 2.3%, and 1.6%, respectively, were obtained (n ϭ 19). Serum folic acid and vitamin B 12 were measured by competitive protein binding enzyme immunoassays on the Centaur analyser (Bayer Diagnostics, Newbury, UK). Serum creatinine and cholesterol were measured using manufacturer's standard methods on the Advia 1650 analyzer (Bayer Diagnostics).
Statistical Analysis
Data are presented as means Ϯ SEM and 95% confidence intervals (CI). The means of baseline normally distributed variables in the placebo and folic acid groups were compared by Student unpaired t test. The FABF changes during each infusion rate were expressed as a ratio between the infused and control forearm (FABFR), that is, a ratio Ͼ1 indicated vasodilatation in the infused forearm. The FABFR changes during acetylcholine and sodium nitroprusside infusions were assessed by ANOVA for repeated measurements with Bonferroni's correction for multiple comparisons. The treatment-induced changes in biochemical and hemodynamic parameters in the placebo group were compared to those in the folic acid group by using the Mann-Whitney U test. Correlations between changes in folic acid and homocysteine concentrations were assessed by Pearson's correlation coefficients. Finally, a backward stepwise regression analysis was performed to identify independent predictors of endothelium-dependent FABFR changes (SPSS for Windows 11.0, SPSS Inc., Chicago, IL). Factors included were age, diabetes duration, presence of hypertension, changes in folic acid and plasma homocysteine concentrations. A P value less than .05 indicated statistical significance.
Results
The baseline characteristics, illustrated in Table 1 , show that the placebo and folic acid groups were well balanced. No adverse effects were reported during the treatment period. No significant changes in serum cholesterol, plasma glucose, glycated hemoglobin, and BP were observed in the folic acid and placebo groups. As expected, folic acid supplementation reduced both plasma homocysteine concentrations and homocysteine:creatinine ratio (Table 2) . Changes in folic acid and homocysteine concentrations were significantly and negatively correlated (r ϭ Ϫ0.75, P Ͻ .001).
No changes in absolute baseline FABF values were observed in the placebo and folic acid groups before and after treatment (placebo group control arm 3.9 Ϯ 0.3 v 3.4 Ϯ 0.3 mL/100 g/min; infused arm 3.7 Ϯ 0.3 v 3.6 Ϯ 0.2 mL/100 g/min; folic acid control arm 3.7 Ϯ 0.5 v 4.0 Ϯ 0.5 mL/100 g/min; folic acid infused arm 3.9 Ϯ 0.6 v 3.9 Ϯ 0.5 mL/100 g/min). Intra-arterial administration of acetylcholine and sodium nitroprusside induced a progressive vasodilatation (ie, FABF ratio Ͼ1; Fig. 1 ). As expected, the endotheliumindependent vasodilator sodium nitroprusside induced a greater vasodilatation than the endothelium-dependent vasodilator acetylcholine (Fig. 1) Fig. 1 ). Changes in folic acid concentrations were positively correlated with changes in maximal endothelium-dependent vasodilatation (r ϭ 0.45, P ϭ .037). In contrast, changes in homocysteine concentrations did not correlate with changes in maximal endothelium-dependent vasodilatation, although a trend was noted (r ϭ Ϫ0.35, P ϭ .144). Multiple regression analysis showed that changes in folic acid, but not homocysteine, described the changes in maximal endothelium-dependent vasodilatation (R 2 ϭ 0.28, P ϭ .021).
Folic acid did not induce significant changes in endothelium-independent vasodilatation, carotid-radial, and carotid-femoral PWV (Table 2) . No significant changes in FABFR and PWV were observed in the placebo group ( Fig. 1 and Table 2 ).
Analysis of FABF and PWV after exclusion of subjects receiving insulin (n ϭ 6) yielded similar results. 
Discussion
Short-term oral supplementation with folic acid significantly enhanced endothelium-dependent acetylcholinemediated vasodilatation in patients with type 2 diabetes. In contrast, no significant effects on large artery stiffness were observed. To our knowledge, this is the first study to investigate the combined endothelial and pulse wave velocity effects of oral folic acid in type 2 diabetes.
A selective impairment of endothelium-dependent vasodilatation has been demonstrated in type 2 diabetes. 4 This phenomenon is due to a reduction in nitric oxide (NO) availability. 17 High glucose concentrations increase oxygen radical formation in endothelial cells, thus causing enhanced NO degradation. 18 The NO-producing enzyme, endothelial NO synthase (eNOS), in the presence of hyperglycemia can "switch" from chiefly NO synthesis to production of superoxide. 18 Other factors potentially con-tributing to reduced NO availability and endothelial dysfunction in type 2 diabetes are the co-existence of dyslipidemia, obesity, and hypertension. 19 However, endothelial dysfunction has been also demonstrated in type 2 diabetic patients without hypertension and after adjusting for obesity. 4 Moreover, the results of studies assessing the effects of lipid-lowering treatment on endothelial function in type 2 diabetes have not been consistent, suggesting that other factors might play a role. 20, 21 Endothelial dysfunction is a strong and independent predictor of mortality in patients with type 2 diabetes followed up for 9 years, even after correcting for urinary albumin excretion and markers of inflammation. 22 Therefore, strategies aimed at ameliorating endothelial function might provide cardiovascular protection in these patients.
Homocysteine, a highly reactive sulfur-containing amino acid, is an independent predictor of endothelial dysfunction by reducing NO availability. 8, 23 Homocysteine augments superoxide production and reduces NO availability in aortic rings of diabetic rabbits. 24 The reduction in plasma homocysteine concentrations after folic acid supplementation might potentially ameliorate endothelial function in type 2 diabetes. However, although a biologically and statistically significant reduction in ho- Ach ϭ acetylcholine; ACR ϭ albumin:creatinine ratio; BP ϭ blood pressure; FABFR ϭ forearm arterial blood flow ratio; HbAlc ϭ glycated haemoglobin; PWV ϭ pulse wave velocity; SNP ϭ sodium nitroprusside. Data are expressed as means Ϯ SEM (95% CI).
mocysteine concentrations was observed in the subjects receiving folic acid, changes in homocysteine were not significantly related to the changes in maximal endothelial-dependent vasodilatation both in univariate and multivariate analyses. In contrast, changes in folic acid concentrations described the improvement in endothelialdependent vasodilatation, suggesting that folic acid exerts beneficial effects on the endothelium that are independent of the homocysteine-lowering effects. The "direct" endothelial effects of folic acid have been recently observed in other studies by our group and others. 13, 25 Plasma glucose concentrations were moderately elevated at the time of the assessment, which may have an effect on endothelial function. However, these are moderate increases commonly seen in type 2 diabetes and reflect the everyday clinical situation. Furthermore, there were no differences in plasma glucose concentrations between the groups or after folic acid supplementation making the possibility of glycemia-induced changes in eNOS activity and, hence, endothelial function, very unlikely. Six of the study subjects were on insulin therapy. This might have affected our findings, given the effects of this hormone on blood flow and vasodilatation. 26 However, a repeated analysis after exclusion of subjects receiving insulin yielded similar results.
By what mechanisms could folic acid exert "direct" effects on the endothelium? Oxidative modification of the eNOS co-factor tetrahydrobiopterin (BH 4 ) seems to be a key factor in the "uncoupling" of this enzyme with a consequent increased production of superoxide anion rather than NO. 27 The BH 4 supplementation can restore eNOS function, reduce vascular oxidative stress, and enhance endothelial function. 28 Interestingly, in vitro experiments have also demonstrated that 5-methyltetrahydrofolate (5-MTHF), the active form of folic acid, can also influence the enzymatic activity of eNOS by reducing superoxide generation and increasing NO synthesis. 29 The presence of a pteridine-binding domain in NO synthase with similarities with the folic acid binding site of dihydrofolate reductase has been reported. 30 Recently, the local intra-arterial administration of 5-MTHF has been shown to acutely enhance endothelial function in patients with type 2 diabetes. 31 The results of our study provide additional information by demonstrating that 1) oral supplementation with folic acid provides beneficial effects on endothelial function that are not limited to the acute phase but persist after 4 weeks of treatment; 2) folic acid does not affect arterial stiffening; and 3) the effects of folic acid are independent of homocysteine lowering.
Of note, the patients with type 2 diabetes enrolled in our study had not had previous cardiovascular events, the duration of their diabetes was only 5 years on average, and their BP and metabolic control were satisfactory. This might at least partly explain the effectiveness of folic acid on endothelial function. In fact, the ameliorative influence on eNOS suggests a more pronounced effect in the early phases of atherogenesis, and less benefit in the more advanced phases, given the reduced eNOS expression in more advanced atherosclerosis. 32 Folic acid did not have significant effects on large artery stiffness. There is evidence that basal NO production influence large artery stiffness. Local administration of acetylcholine acutely reduces pulse wave velocity Table 2 . Changes in clinical, biochemical, and hemodynamic parameters after treatment with placebo and folic acid Parameter Placebo (n ‫؍‬ 13) Folic Acid (n ‫؍‬ 13) P mainly through NO production, 33 suggesting that interventions aimed at increasing NO production might theoretically reduce arterial stiffness. Although increased plasma homocysteine concentrations are associated with arterial stiffening, intervention studies using folic acid to lower homocysteine concentrations have provided conflicting results. 13, 14, 34 It is possible that longer periods of supplementation with folic acid, perhaps associated with a tight BP and metabolic control, are required to revert some of the arterial wall structural abnormalities associated with arterial stiffening, such as fibrosis and smooth muscle cell hypertrophy.
The limitations of our study are related to the relatively small sample size, the short period of supplementation, and the lack of "hard" end points such as cardiovascular morbidity and mortality. Larger trials are warranted to establish whether chronic folic acid supplementation will significantly reduce cardiovascular end points in patients with type 2 diabetes.
FIG. 1
Forearm arterial blood flow ratios between the infused and control arm at baseline and during acetylcholine and sodium nitroprusside infusions before and after treatment. (OE) Acetylcholine baseline; () acetylcholine after treatment; (□) sodium nitroprusside baseline; () sodium nitroprusside after treatment. FABFR ϭ forearm arterial blood flow ratio; Ach ϭ acetylcholine; SNP ϭ sodium nitroprusside. Means Ϯ SEM; *P Ͻ .05; **P Ͻ .01 v baseline.
